Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

159 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-12

Study Completion Date

2024-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of different dose levels of modified messenger ribonucleic acid (mRNA) vaccines encoding full length hemagglutinin (HA) sequence of influenza virus encapsulated in lipid nanoparticles (LNPs) (hereafter referred to as HA mRNA vaccines) compared to control(s). The HA mRNA vaccine candidates and control(s) are presented in the substudy protocols.

The aim is to generate clinical data across different substudies to provide learnings regarding the mRNA technology to support optimization of the mRNA platform including mRNA and LNP design and to support the decision of LNP and dose selection for future projects using mRNA technology.

The purpose of this Substudy 01 is to evaluate the safety and immunogenicity of a single IM injection of up to 5 dose levels of a monovalent modified mRNA encoding the full-length HA sequence of A/Tasmania/503/2020 (H3N2) influenza virus encapsulated in LNP (hereafter referred to as H3 mRNA /LNP) administered as a single intramuscular (IM) injection in adults 18 to 49 years of age and 60 years of age and above, compared to the following active control: a quadrivalent recombinant influenza vaccine (RIV4).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT05227001

Influenza, Human

COMPLETED PHASE1

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

NCT01746082

Influenza

COMPLETED PHASE2

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632

SARS-CoV-2 Influenza RSV

COMPLETED PHASE1

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174

Influenza Immunization Healthy Volunteers

COMPLETED PHASE1

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606

Influenza Immunization

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study duration per participant will be approximately 6 months with 1 injection of one of the different HA mRNA vaccines or control for each substudy and a dose-escalation with sequential enrollment (sentinel cohort followed by main cohort).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Immunization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

This study will be blinded to participants and sites (except for those preparing/administering study interventions. The sponsor will be unblinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: H3 mRNA /LNP dose 1

Participants will receive one intramuscular (IM) dose of H3 mRNA/LNP at Day 01

Group Type EXPERIMENTAL

H3 mRNA / LNP Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Group 2: H3 mRNA /LNP dose 2

Participants will receive one IM dose of H3 mRNA/LNP at Day 01

Group Type EXPERIMENTAL

H3 mRNA / LNP Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Group 3: H3 mRNA /LNP dose 3

Participants will receive one IM dose of H3 mRNA/LNP at Day 01

Group Type EXPERIMENTAL

H3 mRNA / LNP Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Group 4: H3 mRNA /LNP dose 4

Participants will receive one IM dose of H3 mRNA/LNP at Day 01

Group Type EXPERIMENTAL

H3 mRNA / LNP Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Group 5: H3 mRNA /LNP dose 5

Participants will receive one IM dose of H3 mRNA/LNP at Day 01

Group Type EXPERIMENTAL

H3 mRNA / LNP Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Group 6 (Control Group): RIV4 dose

Participants will receive one IM dose of RIV4 at Day 01

Group Type ACTIVE_COMPARATOR

Quadrivalent recombinant influenza Vaccine (RIV4)

Intervention Type BIOLOGICAL

Pharmaceutical Form: Solution for injection in a pre-filled syringe

Route of Administration: Intra-Muscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H3 mRNA / LNP Vaccine

Pharmaceutical Form: Suspension for injection

Route of Administration: Intra-Muscular

Intervention Type BIOLOGICAL

Quadrivalent recombinant influenza Vaccine (RIV4)

Pharmaceutical Form: Solution for injection in a pre-filled syringe

Route of Administration: Intra-Muscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Flublok Quadravalent®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years and above on the day of inclusion

\*Aged 18 years to 49 years or 60 years and above on the day of inclusion (substudy 01)
* A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

* Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.

OR

• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

* A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) at the screening visit.

Participants are eligible for the study only if all of the following criteria are met:

A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.

OR

• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the first dose of study intervention.

Exclusion Criteria

* Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
* Any screening laboratory parameter with laboratory abnormalities that are greater than Grade 1 or deemed clinically significant in the opinion of the Investigator

* OR, any screening Liver Function Test (ALT, AST, Bilirubin) \> 1.2x Upper Limit of Normal or any other screening laboratory parameter outside of the range of normal limits for age and gender
* Positive test for human immunodeficiency virus (HIV) antigen and/or antibodies (Abs), hepatitis B (HB) virus surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), or hepatitis C virus antibodies (HCV Abs)
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
* Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol \[PEG\], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA COVID-19 vaccine
* Previous history of myocarditis, pericarditis, and/or myopericarditis
* Screening electrocardiogram (ECG) or troponin value that is consistent with probable or possible myocarditis, pericarditis, and/or myopericarditis or screening ECG that demonstrates clinically relevant abnormalities that may affect participant safety or study results
* Self-reported thrombocytopenia, contraindicating intramuscular vaccination based on Investigator's judgment
* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on Investigator's judgment
* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
* Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
* Receipt of any vaccine in the 4 weeks preceding study enrollment or planned receipt of any vaccine in the 4 weeks following study intervention administration
* Receipt of any mRNA vaccine/product in the 2 months preceding study enrollment or planned receipt of any mRNA vaccine/product within the 2 months following study intervention administration
* Receipt of immune globulins, blood or blood-derived products in the past 3 months -Participation at the time of study enrollment (or in the 4 weeks preceding study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
* Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine

* Moderate or severe acute illness/infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C \[100.4°F\]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes